VALUE PROPOSITION: * Consolidated benefits of Market Access and HEOR consulting * Enhanced market access for pharmaceutical products * Improved understanding of product value proposition * Optimization of pricing and reimbursement strategies * Strengthened evidence base for product differentiation
Value Proposition
VALUE CREATION: European Pricing and Reimbursement strategy for rare disease asset STRATEGIC PLANNING & PROJECT MANAGEMENT: HTA programmes (NICE, SMC & NCPE) for rare disease assets and haem-oncology asset VALUE CREATION & PROJECT MANAGEMENT: UK HTA (NICE) strategy development and timely execution for neurology asset and diabetes asset BIG DATA & ANALYTICS PROJECT MANAGEMENT: Real-world evidence to support the market access and value proposition of their oncology assets ANALYTICS & VALUE CREATION: Innovative tool updating and development (Burden of disease and budget impact models) GOVERNANCE & COMPLIANCE: Clinical auditing of private clinic ensuring highest standards are met for patient care
Some recent project type examples
Worked on 25+ assets (brands) in various therapeutic areas: - Metabolic (diabetes, cardiovascular) - Oncology (urothelial cancer, prostate cancer, colorectal cancer) - Immuno-oncology (gastric or GEJ cancer) - Haem-oncology (AML) - Haemotology (haemophilia) - Neurology – Parkinson’s Disease, NMOSD (RD), epilepsy, schizophrenia, - Nephrology – CKD with anaemia, lupus nephritis (RD) - Biosurgery - Women’s Health (HRT) Open to contributing to new therapeutic areas due to keen interest and competent Pharmacy background. [RD: Rare Disease]
Therapeutics areas and assets/brands